FindTrial
Sign In

Robust production of virus specific cytotoxic T lymphocytes

Development of technology for robust production of latent virus specific cytotoxic T lymphocytes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001713
Enrollment
10
Registered
2015-12-02
Start date
2015-11-30
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria include: 1. Signed informed consent form approved by the KCMC IRB. 2. Age 20 to 75 years,

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Unable to provide informed consent 2. Ages under 20 or over 75 3. HIV positive individuals or either HBV or HCV positive individuals 4. Individuals with systemic or active infections requiring medical attention 5. Individuals who had previously participated in a blood donation of 200mL to 400mL within the past three months

Design outcomes

Primary

MeasureTime frame
Phenotype, Purity—

Secondary

MeasureTime frame
In vitro cytotoxicity effect—

Countries

Korea, Republic of

Contacts

Public ContactNayoun Kim

The Catholic University of Korea

nancynayounkim@gmail.com+82-2-2258-6907

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026